Why Veterinary Drugs Are Not Cleared for Human Use

Regulatory explainer · Last updated November 6, 2026

“If it’s safe enough for my dog, why won’t they let me take it?” The question is understandable, and answering it honestly requires explaining what a drug approval actually is. An approval is not a statement that a molecule is harmless. It is a specific license: this product, at these doses, for these conditions, in this species, offers benefits that outweigh its risks. Change any variable — species, dose, duration, co-medications, indication — and the license no longer describes the situation.

What veterinary approval covers

To approve an animal drug, agencies like the FDA’s Center for Veterinary Medicine evaluate the target animal’s physiology, the drug’s safety margin in that species, residues in food animals, and manufacturing consistency for the marketed formulation. Fenbendazole passed this process for dogs, horses, cattle, and other species as a dewormer. None of that process studied humans. Dogs clear many drugs faster or slower than people do; their gut physiology, body mass, and typical lifespan all differ. A tolerance study in a healthy beagle answers a different question than a cancer patient’s six months of continuous use alongside chemotherapy.

What human approval would require

To become a human cancer medicine, a compound must climb the full ladder: laboratory studies, animal toxicology under Good Laboratory Practice, then phased human trials — safety and dosing (phase I), early signals of effect (phase II), and randomized controlled comparison against existing care (phase III). Each stage filters out candidates, and the cost of the process is precisely why “no trial exists” is meaningful information rather than evidence of conspiracy. Drug repurposing — testing old drugs in new diseases — is a legitimate, actively published strategy, and cousin benzimidazoles such as mebendazole have entered human brain-tumor trials. Fenbendazole has not completed a single human cancer trial.

Quality and the gray market

Human pharmaceuticals are manufactured under Good Manufacturing Practice: identity testing, purity limits, stability data, tamper-evident packaging, and post-market adverse-event reporting. Animal products are held to animal-drug standards — lower-cost formulations, different excipients, no human-pharmaceutical batch requirements. When viral demand spikes, gray-market resellers appear, and the product a patient buys online may be expired, mislabeled, counterfeit, or simply inconsistent. Unlike a prescription drug, there is no pharmacovigilance system tracking what these products do in people — so harms surface late, if at all. The documented adverse-event record is therefore a floor, not a ceiling.

The precedent regulators remember: ivermectin

The closest recent example is ivermectin, another antiparasitic that went viral as a treatment for a different disease, COVID-19. The FDA issued letters and warnings as people dosed themselves with concentrated animal formulations; poison-control systems recorded overdoses. The lesson regulators drew — visible again in ASCO’s 2026 clinical notice on ivermectin and fenbendazole in cancer — is that viral anecdotes about animal drugs outrun the evidence quickly, and that clear warnings save lives.

What the major bodies say

In 2026, the American Society of Clinical Oncology published a clinical notice recommending against ivermectin and fenbendazole for cancer treatment or as adjuncts outside of clinical trials. The American Cancer Society’s explainer states that fenbendazole “has not been tested for use in humans as a cancer treatment.” The FDA’s Center for Veterinary Medicine has itself documented adverse events from extra-label use in dogs. These statements are aligned, sourced, and unusually blunt for regulatory communication — worth reading in the originals, which we link below.

Where does that leave an individual patient? Not stuck between “obedience” and “self-experimentation.” The productive middle path is the conversation: bring the evidence — or the questions — to your oncologist. Our guide includes exactly which questions to ask.

What “extra-label” means — and why it does not help here

In veterinary practice, “extra-label” (off-label) use means a licensed veterinarian prescribes an approved animal drug differently than its label specifies — a different dose, duration, or species — based on their clinical judgment of a specific animal. Crucially, that framework assumes a licensed professional examining the actual patient, choosing a dose for that animal, and monitoring the outcome. Self-directed use of an animal dewormer, purchased online, at doses copied from forums, has none of those safeguards: no examination, no individualized dosing, no monitoring, and no professional accountability when something goes wrong. The FDA’s 2024 letter on marrow toxicity in dogs concerned exactly this territory — extra-label use — and even with a veterinarian nominally in the loop, harm was still reported. Removing the veterinarian does not widen the safety margin; it removes the only person positioned to notice one narrowing.

Sources